Anti-tumor necrosis factor (anti-TNF-α) are a group of new drugs able to inhibit the action of this cytokine. Although systemic side effects have been well described, cutaneous adverse reactions have not yet been clearly elucidated. The authors report a case of a 29-year-old man affected by Crohn disease and ankylosing spondylitis who developed psoriatic lesions after IV infusion of infliximab 5 mg/Kg. The patient underwent cyclosporine treatment after interruption of biological therapy, and had complete resolution of cutaneous lesions. The reason for this phenomenon is not clear, Obviously more studies are necessary to define more clearly this paradoxical reaction. In addition, dermatologists must be informed about this potential cutaneous adverse event.
A case of infliximab-induced psoriasis / Richetta, Antonio Giovanni; C., Mattozzi; V., Maiani Carlomagno; V., Carboni; S., Giancristoforo; S., D'Epiro; F., Bruni; Calvieri, Stefano. - In: DERMATOLOGY ONLINE JOURNAL. - ISSN 1087-2108. - 14:11(2008), pp. 9-9.
A case of infliximab-induced psoriasis
RICHETTA, Antonio Giovanni;CALVIERI, Stefano
2008
Abstract
Anti-tumor necrosis factor (anti-TNF-α) are a group of new drugs able to inhibit the action of this cytokine. Although systemic side effects have been well described, cutaneous adverse reactions have not yet been clearly elucidated. The authors report a case of a 29-year-old man affected by Crohn disease and ankylosing spondylitis who developed psoriatic lesions after IV infusion of infliximab 5 mg/Kg. The patient underwent cyclosporine treatment after interruption of biological therapy, and had complete resolution of cutaneous lesions. The reason for this phenomenon is not clear, Obviously more studies are necessary to define more clearly this paradoxical reaction. In addition, dermatologists must be informed about this potential cutaneous adverse event.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
